Yuyu Pharma, Inc.
000227.KS
Korea Exchange8,610.00
KRW
+210.00
- -
Yuyu Pharma, Inc.
000227.KS
(Korea Exchange)
Recent
price
8,610.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Yuyu Pharma, Inc. is a South Korea-based specialty pharmaceutical company engaged in the development, manufacture, and marketing of pharmaceutical products, medical devices, and health-related goods. The company offers a broad portfolio of prescription drugs, non-prescription drugs, quasi-drugs, dietary supplements, and medical foods across therapeutic areas such as neurology, urology, respiratory, cardiovascular, and bone health. Key products include novel small oral formulations like Dutasteride and Tadalafil combination tablets for benign prostatic hyperplasia and improved medicines for osteoporosis and anti-thrombosis. Yuyu Pharma also delivers over-the-counter products such as YupanC (vitamin C), Venoplus ointment, and Venapollo multivitamins. With operations primarily in South Korea and expanding across Asia-Pacific and Latin American markets, the company maintains manufacturing facilities and an R&D center focused on new drug discovery programs for conditions like benign prostatic hyperplasia and dry eye syndrome. Founded in 1941, Yuyu Pharma is headquartered in Seoul, South Korea. In recent strategic developments, Yuyu Pharma has significantly expanded into the global animal health sector through a strategic investment in Dalan Animal Health, a U.S.-based biotechnology company specializing in innate immunity-based vaccine platforms for honeybees and shrimp, including the world’s first USDA-approved honeybee vaccine and a novel shrimp vaccine aimed at global aquaculture disease management. This investment reflects Yuyu Pharma’s strategic intent to become a global leader in veterinary biologics and sustainable food-system technologies. Additionally, the company has broadened its animal health portfolio with recent investments in VetmAb Bio, a developer of species-specific monoclonal antibodies for dogs and cats, and DogPPL, a U.S.-based premium pet wellness platform. These moves mark Yuyu Pharma’s shift towards engaging in innovative biotechnology and pet wellness markets alongside its traditional pharmaceutical business, aligning with emerging trends in biologics, sustainable aquaculture, and companion animal care. The company’s strategic investments, ongoing product developments, and global expansion initiatives define its current business trajectory and growth ambitions in both human and animal health sectors.